Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

A Multi-Institutional Retrospective Analysis of Tyrosine Kinase Inhibitor (TKI) Clinical and Preclinical Efficacy According to BCR-ABL Mutation Status in CP-CML Patients

Victor M. Rivera, Susan Branford, Franck E. Nicolini, Justin R. Pritchard, Joseph M. Gozgit, Wolfgang Kern, MD, Dragana Milojkovic, Simone Claudiani, Martin C. Muller, Srinivas K Tantravahi, Michael W. Deininger, Michael Heinrich, Simona Soverini, Michele Baccarani, Jerald P. Radich, Elias Jabbour, Jorge E. Cortes, Gabriel Etienne, Torsten Haferlach

Blood (2015) 126 (23): 2790.

https://doi.org/10.1182/blood.V126.23.2790.2790

Published: 2015

Journal Articles

Potent Preclinical Activity of Ponatinib in Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma (GCB-DLBCL) Models

Joseph M. Gozgit, Youngchul Song, Scott Wardwell, Sara Nadworny, Yaoyu Ning, Victor M. Rivera

Blood (2015) 126 (23): 4000.

https://doi.org/10.1182/blood.V126.23.4000.4000

Published: 2015

Journal Articles

Comparative TKI Profiling Analyses to Explore Potential Mechanisms of Ponatinib-Associated Arterial Thrombotic Events

Victor M. Rivera, PhD, Justin R. Pritchard, PhD, Francois Gonzalvez, PhD, Theresa Baker, Joseph M. Gozgit, PhD, Graeme Hodgson, PhD

Blood (2014) 124 (21): 1783.

https://doi.org/10.1182/blood.V124.21.1783.1783

Published: 2014

Journal Articles

Comprehensive Analysis Of The In Vitro Potency Of Ponatinib, and All Other Approved BCR-ABL Tyrosine Kinase Inhibitors (TKIs), Against a Panel Of Single and Compound BCR-ABL Mutants

Joseph M Gozgit, PhD, Alexa Schrock, PhD, Tzu-Hsiu Chen, Tim Clackson, PhD, Victor M. Rivera, PhD

Blood (2013) 122 (21): 3992.

https://doi.org/10.1182/blood.V122.21.3992.3992

Published: 2013

Journal Articles

Effects of a Novel, Selective Jak2 Inhibitor, AZ60, on STAT5 Signaling and Cellular Growth in Jak2 V617F Cell Lines.

Joseph M. Gozgit, PhD, Geraldine A. Bebernitz, BS, Pankaj Patil, MS, Minwei Ye, MS, Jiaquan Wu, PhD, Stephanos Ioannidis, PhD, Audrey Davies, BS, Tao Wang, PhD, Dennis Huszar, PhD, Michael Zinda, PhD

Blood (2007) 110 (11): 3549.

https://doi.org/10.1182/blood.V110.11.3549.3549

Published: 2007

NARROW

A Multi-Institutional Retrospective Analysis of Tyrosine Kinase Inhibitor (TKI) Clinical and Preclinical Efficacy According to BCR-ABL Mutation Status in CP-CML Patients

Potent Preclinical Activity of Ponatinib in Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma (GCB-DLBCL) Models

Comparative TKI Profiling Analyses to Explore Potential Mechanisms of Ponatinib-Associated Arterial Thrombotic Events

Comprehensive Analysis Of The In Vitro Potency Of Ponatinib, and All Other Approved BCR-ABL Tyrosine Kinase Inhibitors (TKIs), Against a Panel Of Single and Compound BCR-ABL Mutants

Effects of a Novel, Selective Jak2 Inhibitor, AZ60, on STAT5 Signaling and Cellular Growth in Jak2 V617F Cell Lines.

Email alerts

ASH Publications

American Society of Hematology

A Multi-Institutional Retrospective Analysis of Tyrosine Kinase Inhibitor (TKI) Clinical and Preclinical Efficacy According to BCR-ABL Mutation Status in CP-CML Patients

Potent Preclinical Activity of Ponatinib in Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma (GCB-DLBCL) Models

Comparative TKI Profiling Analyses to Explore Potential Mechanisms of Ponatinib-Associated Arterial Thrombotic Events

Comprehensive Analysis Of The In Vitro Potency Of Ponatinib, and All Other Approved BCR-ABL Tyrosine Kinase Inhibitors (TKIs), Against a Panel Of Single and Compound BCR-ABL Mutants

Effects of a Novel, Selective Jak2 Inhibitor, AZ60, on STAT5 Signaling and Cellular Growth in Jak2 V617F Cell Lines.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only